Xenon Pharmaceuticals XENE Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Xenon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xenon Pharmaceuticals's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xenon Pharmaceuticals's additional paid-in capital?
- Xenon Pharmaceuticals (XENE) reported additional paid-in capital of $264.88M in Q1 2026.
- How has Xenon Pharmaceuticals's additional paid-in capital changed year-over-year?
- Xenon Pharmaceuticals's additional paid-in capital increased by 27.1% year-over-year, from $208.46M to $264.88M.
- What is the long-term trend for Xenon Pharmaceuticals's additional paid-in capital?
- Over 5 years (2020 to 2025), Xenon Pharmaceuticals's additional paid-in capital has grown at a 38.1% compound annual growth rate (CAGR), from $45.36M to $228.23M.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.